Perrigo (PRGO) Cost of Revenue (2012 - 2026)
Perrigo (PRGO) posted quarterly Cost of Revenue of $22.6 million for Q1 2026, down 96.53% year-over-year from $651.6 million in Q1 2025, and up 101.18% quarter-over-quarter from -$1.9 billion in Q4 2025.
Perrigo (PRGO) Cost of Revenue (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Cost of Revenue for 15 consecutive years, with $22.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue fell 96.53% year-over-year to $22.6 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 262.49% YoY), while the FY2025 annual figure was $93.4 million, down 4.69% from the prior year.
- Cost of Revenue advanced to $22.6 million in Q1 2026 per PRGO's latest filing, from -$1.9 billion in the prior quarter.
- Across five years, Cost of Revenue topped out at $765.1 million in Q3 2023 and bottomed at -$2.1 billion in Q4 2022.
- Historically, Cost of Revenue has averaged -$10.3 million across 5 years, with a median of $25.5 million in 2023.
- Annual changes were most pronounced in 2022 — Cost of Revenue jumped 3310.65% — and 2025, when it plunged 8330.9%.
- Perrigo's Cost of Revenue stood at -$2.1 billion in 2022, then soared by 101.21% to $25.5 million in 2023, then slipped by 8.63% to $23.3 million in 2024, then slumped by 8330.9% to -$1.9 billion in 2025, then surged by 101.18% to $22.6 million in 2026.
- Business Quant data shows PRGO's Cost of Revenue at $22.6 million in Q1 2026, -$1.9 billion in Q4 2025, and $24.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Perrigo | 1.89 Bn | 1.49 Bn | 313.90 Mn | 708.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 708.90 Mn |
| Jun 27, 2026 | 708.90 Mn |
| Mar 28, 2026 | 22.60 Mn |
| Mar 28, 2026 | 22.60 Mn |
| Dec 31, 2025 | -1.92 Bn |
| Dec 31, 2025 | -1.92 Bn |
| Sep 27, 2025 | 24.20 Mn |
| Sep 27, 2025 | 24.20 Mn |
| Jun 28, 2025 | 693.40 Mn |
| Jun 28, 2025 | 693.40 Mn |
| Mar 29, 2025 | 651.60 Mn |
| Mar 29, 2025 | 651.60 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 28, 2024 | 25.20 Mn |
| Sep 28, 2024 | 25.20 Mn |
| Jun 29, 2024 | 24.60 Mn |
| Jun 29, 2024 | 24.60 Mn |
| Mar 30, 2024 | 24.90 Mn |
| Mar 30, 2024 | 24.90 Mn |